HELP · Cybin Inc. Common Stock
View on chartInsiders & Stakes
| So Eric H. L. Executive Chair | ▲ Buy | Open Market | 4,465,014 Shares held | 9/8/2026 | View profile |
| Glavine Paul Chief Growth Officer | ▲ Buy | Open Market | 4,271,252 Shares held | 9/8/2026 | View profile |
| Halstead Michael Chief Executive Officer | ▲ Buy | Open Market | 168,568 Shares held | 9/21/2026 | View profile |
Transaction History
| Halstead Michael | ▲ Buy | Open Market | 100,000 | $1.3M | 9/21/2026 |
| Glavine Paul | ▲ Buy | Open Market | 100,000 | $1.2M | 9/8/2026 |
| Glavine Paul | ▲ Buy | Open Market | 100,000 | $1.2M | 9/8/2026 |
| So Eric H. L. | ▲ Buy | Open Market | 100,000 | $1.2M | 9/8/2026 |
| So Eric H. L. | ▲ Buy | Open Market | 100,000 | $1.2M | 9/4/2026 |
| Glavine Paul | ▲ Buy | Open Market | 100,000 | $1.2M | 9/3/2026 |
| So Eric H. L. | ▲ Buy | Open Market | 95,000 | $1.1M | 9/1/2026 |
| Glavine Paul | ▲ Buy | Open Market | 90,000 | $1.0M | 8/31/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cybin shareholders approve rebrand to Helus Pharma
Cybin shareholders recently approved a plan to change the company's name to Helus Pharma, effective October 1, 2026. This rebrand coincides with the company's focus on its HLP-003 drug for major depression, which is awaiting Phase III data. While the stock has seen fresh attention, analysts note it may be trading at a premium relative to its current valuation metrics.
Cybin shareholders approve rebrand to Helus Pharma. Cybin shareholders recently approved a plan to change the company's name to Helus Pharma, effective October 1, 2026. This rebrand coincides with the company's focus on its HLP-003 drug for major depression, which is awaiting Phase III data. While the stock has seen fresh attention, analysts note it may be trading at a premium relative to its current valuation metrics.